For intermediate-risk patients, US + AFP and AMRI were optimal for female patients depending on the patient type (e.g., AMRI preferred for obese patients with Child-Pugh A cirrhosis), and GALAD was optimal for male patients. This evidence concerns the gene AFP and Cirrhosis.